Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KQB365 |
| Synonyms | |
| Therapy Description |
KQB365 inhibits mutant KRAS, which potentially induces apoptosis and decreases proliferation in tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KQB365 | KQB-365|KQB 365 | KRAS Inhibitor 30 | KQB365 inhibits mutant KRAS, which potentially induces apoptosis and decreases proliferation in tumor cells harboring KRAS mutations (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06720987 | Phase I | Cetuximab + KQB365 KQB365 | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Recruiting | USA | 0 |